文献速递甲状腺疾病

达拉非尼联合曲美替尼治疗BRAFK601E突变低分化甲状腺癌的再分化

Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment.
PubMed 文献 · Thyroid · 2019-01-01

一例59岁女性局部侵袭性低分化甲状腺癌伴肺、纵隔及骨转移且存在体细胞BRAFK601E突变、有抗血管生成药物禁忌的患者接受达拉非尼联合曲美替尼治疗。治疗期间甲状腺球蛋白升高、出现临床甲亢,FDG-PET显示代谢缓解而形态学稳定,放射性碘全身扫描显示转移灶高摄碘,活检示分化改善、钠碘同向转运体表达增加;因甲亢导致一般状态下降而停药。

要点

  • BRAFK601E突变低分化甲状腺癌患者接受达拉非尼联合曲美替尼治疗可出现再分化。
  • 再分化表现为摄碘能力恢复和分化标志物表达增加,但不必然伴随抗肿瘤效应。
  • 治疗中出现的甲亢可导致停药,需密切监测甲状腺功能。

核心结论

  • 本例提示再分化本身不必然与抗肿瘤效应相关。

研究设计与样本

  • 个案报道:一例59岁女性局部侵袭性低分化甲状腺癌伴同步肺、纵隔和骨转移及体细胞BRAFK601E突变患者。

主要发现

  • 治疗第7天起血清甲状腺球蛋白升高,至第4周达基线10倍。
  • 治疗期间出现临床甲亢,游离三碘甲状腺原氨酸和游离甲状腺素分别升至参考上限的6.6倍和4.4倍。
  • 治疗开始后1个月和2个月的FDG PET/CT显示PERCIST代谢缓解,FDG摄取下降82%,而按RECIST标准病变形态学稳定。
  • 在甲亢且血清促甲状腺激素检测不到、无外源性促甲状腺激素刺激条件下进行的诊断性放射性碘全身扫描显示肺、纵隔和颅骨转移灶高摄碘。
  • 治疗开始后2个月活检显示较基线更分化的生长模式且核分裂活性下降,甲状腺球蛋白和甲状腺过氧化物酶在蛋白及mRNA水平均升高,钠碘同向转运体mRNA表达较初始水平增加超过750倍,钠碘同向转运体蛋白表达在治疗下变为可检测。

临床怎么用

  • 对BRAFK601E突变低分化甲状腺癌患者可考虑达拉非尼联合曲美替尼诱导再分化。
  • 治疗中需监测甲状腺功能,甲亢可导致一般状态下降并需停药。

局限性

  • 为单个病例报道,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 59-year-old woman with locally invasive poorly differentiated thyroid cancer with synchronous lung, mediastinal, and bone metastases and a somatic BRAFK601E mutation with contraindication for antiangiogenic drugs was treated with dabrafenib and trametinib. During treatment, serum levels of thyroglobulin increased as early as day 7 up to 10-fold over baseline at week 4. Concurrently, clinical hyperthyroidism occurred, with free triiodothyronine and free thyroxine levels increasing to 6.6 and 4.4 times their upper reference limit. Fludeoxyglucose positron emission tomography/computed tomography at one and two months after treatment initiation showed a PERCIST metabolic response with a 82% decrease in fludeoxyglucose uptake, whereas disease remained morphologically stable according to RECIST criteria. A diagnostic radioactive iodine whole-body scan performed when the patient was thyrotoxic with an undetectable serum thyrotropin level, in the absence of any exogenous thyrotropin stimulation, showed high radioactive iodine uptake in the lung, mediastinum, and skull metastases. A biopsy performed two months after treatment initiation showed a more differentiated growth pattern and a decrease in the mitotic activity compared to baseline. An increase of thyroglobulin and thyroid peroxidase was observed at both the protein and mRNA levels. Sodium-iodide symporter mRNA expression increased by >750 times over its initial level, and sodium-iodide symporter protein expression became detectable under treatment. A decrease in general status due to thyrotoxicosis led to treatment discontinuation. Thyrotoxicosis resolved rapidly and radioactive iodine uptake decreased by >90%. This clinical case shows that redifferentiation itself is not necessarily associated with an antitumor effect.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Leboulleux S, Dupuy C, Lacroix L, et al. Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. Thyroid. 2019. PMID: 30880598. doi:10.1089/thy.2018.0457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。